Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Northern lights chances rise for Christmas as space weather remains unsettled - 2Vote in favor of your Number one method for commending a birthday
- 3NMG signs new graphite supply deal with Canadian Government
- 4Procter & Gamble changes Crest toothpaste packaging to address Texas AG fluoride concerns
- 5James Webb Space Telescope's mysterious 'little red dots' may be black holes in disguise
- German inflation soars to 2.7% in March as Iran war drives up prices
- Eight wounded, cars catch fire in central Israel following strike from Iranian cluster munition
- One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- Why doing good also makes us feel good, during the holidays and beyond
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- Eurovision Song Contest changes voting rules after controversial allegations against Israel
- IDF strikes Tehran command centers, weapon production sites
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Electric Vehicles for Eco-Accommodating Driving
